Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

× No keyword cloud information.

53 in total

Review 1. Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors: Arpi Minassian; Jared W Young
Journal: Expert Opin Pharmacother Date: 2010-08 Impact factor: 3.889

Review 2. Modern antipsychotic drugs: a critical overview.

Authors: David M Gardner; Ross J Baldessarini; Paul Waraich
Journal: CMAJ Date: 2005-06-21 Impact factor: 8.262

3. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?

Authors: Maria B Raeder; Johan Fernø; Audun O Vik-Mo; Vidar M Steen
Journal: Mol Cell Biochem Date: 2006-05-23 Impact factor: 3.396

Review 4. Interventions to reduce weight gain in schizophrenia.

Authors: G Faulkner; T Cohn; G Remington
Journal: Cochrane Database Syst Rev Date: 2007-01-24

Review 5. Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression.

Authors: Angela Y Liu; Tarek K Rajji; Daniel M Blumberger; Zafiris J Daskalakis; Benoit H Mulsant
Journal: Am J Geriatr Psychiatry Date: 2013-07-23 Impact factor: 4.105

Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

Review 1. Evaluation of the clinical efficacy of asenapine in schizophrenia.

Review 2. Modern antipsychotic drugs: a critical overview.

3. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?

Review 4. Interventions to reduce weight gain in schizophrenia.

Review 5. Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression.

6. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Review 7. Quality of medical care for persons with serious mental illness: A comprehensive review.

8. Olanzapine metabolic side effects: a weight gain issue?

9. Treatment response to the RENEW weight loss intervention in schizophrenia: impact of intervention setting.

10. Metabolic syndrome in people with schizophrenia: a review.